MyFinsight
Home
Blog
About
Contact
Download
Download image
Total net loss
attributable to common...
-$28,871K
Net loss
-$26,442K
Effect of warrants
modification, see note 6
$2,429K
Finance income
$1,132K
Operating loss
-$27,574K
Research and development
$18,153K
General and
administrative
$9,421K
Back
Back
Income Statement
source: myfinsight.com
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)